Bambú multicomponent early parenting program to prevent childhood obesity in vulnerable families
Official title: Evaluation of a Tailored Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families (Bambú Project): Randomized Controlled Trial With a Hybrid Type 1 Effectiveness-implementation Design
Run by Avedis Donabedian Research Institute · NCT07529704 · Data updated 2026-11-12
This program tests whether the Bambú multicomponent early parenting intervention in primary care can help prevent excess weight in children aged 6 months to 3 years from vulnerable families where at least one parent has overweight or obesity.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 526 (estimated) |
| Sponsor | Avedis Donabedian Research Institute Academic / other |
| Locations | 4 sites (Burgos, Castille and León and 3 other locations) |
| Status | Recruiting |
| Started | March 2, 2026 |
| Main results expected | June 2028 |
| Study ends | September 2028 |
| Registry record updated | August 5, 2026 |
| Trial ID | NCT07529704 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Primary caregivers aged 18 or older of a healthy term child aged 6 months to 3 years, living in vulnerable socioeconomic circumstances and with at least one parent who has overweight or obesity are ideal candidates.
✕Probably not a fit
Families with children born at low birth weight (<2500 g), from multiple births, or who do not meet the defined vulnerability criteria or cannot attend participating Spanish primary-care sites are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized primary-care intervention compares the Bambú multicomponent parenting program to usual care in families identified as socioeconomically vulnerable and with at least one parent having overweight or obesity. The main outcome is children's BMI-for-age z-score measured at baseline and at 6, 12, and 18 months, with secondary outcomes including responsive feeding, dietary intake, parent and child physical activity, parental eating styles, and child sleep. The intervention is adapted to families' socioeconomic context and delivered through primary-care settings. Eligible participants are primary caregivers aged 18+ of a healthy term child aged 6 months to 3 years who meet predefined vulnerability criteria.
Why it matters
Potential benefit: If successful, the program could help children maintain a healthier weight and establish better feeding, activity, and sleep habits that reduce long-term obesity risk.
How similar studies have gone: Previous randomized early-life multicomponent parenting interventions have shown mixed but promising results for modest reductions in childhood overweight, so this approach builds on emerging evidence but is not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Mothers and/or fathers aged 18 years or older. * Primary caregivers of a healthy child aged 6 months to 3 years, born at term (≥37 weeks of gestation). * At least one parent with overweight or obesity (as defined by BMI criteria). * Families in a situation of vulnerability, defined as meeting ≥1 of the following criteria: (1) Low educational level of at least one parent (≤ lower secondary education or equivalent); (2) Precarious employment situation during the past year, (3) Perceived financial difficulties during the past year; (4) Insecure or unstable housing conditions; (5) Single-parent family or prolonged absence of one of the primary caregivers; (6) Recent immigration (≤10 years) without a stable support network or with language barriers. Exclusion Criteria: * Parents of a child aged 6 months to 3 years with low birth weight (\<2500 g) * Parents of a child aged 6 months to 3 years from a multiple birth (e.g., twins, triplets) * Parents/caregivers of a child aged 6 months to 3 years with congenital conditions, chronic diseases, or severe disabilities that may affect feeding, growth, or participation in the study * Parents or caregivers with severe physical or mental health conditions that would limit their ability to participate in the intervention or assessments * Families planning to move out of the study area during the study period
Where it's running
-
Fundación Avedis Donabedian Para la Mejora de la Calidad Asistencial
Barcelona, Catalonia, Spain Recruiting -
Atenció Primària de Mallorca
Palma de Mallorca, Spain Recruiting -
Servicio Andaluz de Salud
Seville, Spain Recruiting -
Gerencia de Atención Primaria de Burgos
Burgos, Castille and León, Spain Not yet recruiting
Study contacts
- Principal investigator: Carola Orrego, PhD — Avedis Donabedian Research Institute
- Study coordinator: Helena Vall Roqué, PhD
- Email: hvall@fadq.org
- Phone: +34932076608
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
GLP-1 weight‑loss medicine: finding who will benefit most
This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.